NVX-CoV2705
Phase 3Biologic
SanofiNVX-CoV2705 is one of 82 biologic programs targeting Immunogenicity. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
242 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Savaysa
Daiichi SankyoPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Avalglucosidase Alfa
SanofiPhase 3
Hemay005
GGanzhou Hemay Pharmaceutical Co., Ltd
Phase 3
NVX-CoV2705
SanofiPhase 3
IBI302
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NVX-CoV2705. EMBL-EBI & Wellcome Sanger Institute.
- [4]